Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15282119 | 0.93 | GALR3 (0.34) | GALR3KMT2ANPBWR1 | |
| SCHEMBL15282070 | 0.85 | GALR3 (0.33) | GALR3KMT2AKDM4E | |
| SCHEMBL15282182 | 0.84 | GALR3 (0.33) | GALR3 | |
| SCHEMBL4303387 | 0.78 | GALR3 (0.40) | GALR3KMT2AKDM4E | |
| SCHEMBL11405724 | 0.77 | KMT2A (0.38) | GALR3KMT2AKDM4E | |
| SCHEMBL4299859 | 0.75 | MAPT (0.36) | GALR3KMT2A | |
| SCHEMBL13519754 | 0.71 | KMT2A (0.31) | KMT2A | |
| SCHEMBL3095819 | 0.65 | ALDH1A1 (0.33) | GALR3NPBWR1 | |
| SCHEMBL1257988 | 0.65 | GALR3 (0.31) | GALR3 | |
| SCHEMBL3641126 | 0.64 | GALR3 (0.39) | GALR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2644599-B1 | Method for preparing a 2-halo-4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2644599-A1 | Method for preparing 1-substituted-4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-05-24 | — | — | US | disclosed |
| US-8129544-B2 | Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7807843-B2 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| CN-100526300-C | Method of manufacturing 4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| US-7569702-B2 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. | 2008-08-21 | — | — | US | disclosed |
| US-7368579-B2 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | OTSUKA PHARMACEUTICAL CO. LTD. | 2008-04-24 | — | — | US | disclosed |
| CN-1326840-C | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2007-07-18 | — | — | CN | disclosed |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1720838-B1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | EP | disclosed |
| CN-1922154-A | Method for producing 4-nitroimidazole compound | OTSUKA PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1720838-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| CN-1692103-A | 1-substituted-4-nitroimidazole compounds and process for preparing same | OTSUKA PHARMA CO LTD (JP) | 2005-11-02 | — | — | CN | disclosed |
| WO-2005077913-A1 | METHOD FOR PRODUCING 4-NITROIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-25 | — | — | WO | disclosed |
| EP-1553088-A1 | 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME | Otsuka Pharmaceutical Company, Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130082-A1 | 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same | CBR1, CBR3, DCXR | GALR3 3023/4885KMT2A 1236/4885KDM4E 1213/4885 |
| US-20060079697-A1 | 1-substituted-4-nitroimidazole compound and process for producing the same | CBR1, CBR3, DCXR | GALR3 3397/4885KMT2A 1292/4885KDM4E 1016/4885 |
| US-20080200689-A1 | 1-Substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | GALR3 3023/4885KMT2A 1236/4885KDM4E 1213/4885 |
| US-20070161802-A1 | Method for producing 4-nitroimidazole compound | COX4I1, GTF3C5, CYP4X1 | GALR3 3470/4885KMT2A 1832/4885KDM4E 1752/4885 |
| US-20080097107-A1 | 1-substituted-4-nitroimidazole compound and method for preparing the same | CBR1, CBR3, DCXR | GALR3 3023/4885KMT2A 1236/4885KDM4E 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.